Primary and secondary prevention of cervical cancer

Expert Review of Molecular Diagnostics

Volumn 9, Issue 8, 2009, Pages 851-857

  Grce, Magdalena ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Cervical cancer; Human papillomavirus; Prevention; Screening; Vaccination

Indexed keywords

CANCER VACCINE; VIRUS DNA; WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; DRUG EFFICACY; HUMAN; PAPANICOLAOU TEST; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRIMARY PREVENTION; SECONDARY PREVENTION; UTERINE CERVICAL NEOPLASMS;

EID: 70449672945     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.64     Document Type: Review

References (40)

1. Bosch FX, Lorincz A, Muñoz N et al. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55(4), 244-265 (2002). (Pubitemid 34293391)
2. WHO. IARC monographs on the evaluation of carcinogenic risks to humans. human papillomaviruses. WHO Press 90, 1-689 (2007). •• Represents the views and expert opinions of an International Agency for Research on Cancer Working Group on the evaluation of carcinogenic risks to human beings of the human papillomaviruses (HPVs).
3. Basu P, Sarkar S, Mukherjee S et al. Women's perceptions and social barriers determine compliance to cervical screening: results from a population based study in India. Cancer Detect. Prev. 30(4), 369-374 (2006). (Pubitemid 44402902)
4. Stark A, Gregoire L, Pilarski R et al. Human papillomavirus, cervical cancer and women's knowledge. Cancer Detect Prev. 32(1), 15-22 (2008).
5. IARC Working Group on the Evaluation of Cancer Preventive Strategies. Cervix cancer screening. In: IARC Handbooks of Cancer Prevention. (Volume 10). IARC Press, Lyon, France (2005). •• Overview of cervical cancer occurrence, natural history and causes. Provides recommendations for the public health implementation of screening.
6. Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann. Oncol. 18(8), 1423-1425 (2007).
7. Arbyn M, Primic-Zakelj M, Raifu AO et al. The burden of cervical cancer in south-east Europe at the beginning of the 21st Century. Coll. Antropol. 31(Suppl. 2), 7-10 (2007).
8. WHO. Comprehensive Cervical Cancer Control: a Guide to Essential Practice. WHO, Geneva, Switzerland (2006). • Practical guide for cervical cancer prevention for high- and low-income countries.
9. von Karsa L, Anttila A, Ronco G et al. Cancer screening in the European Union. In: Report on the Implementation of the Council Recommendation on Cancer Screening (First Report). International Agency for Research on Cancer, European Communities, Brussels, Belgium (2008). • First report on screening policies in Europe.
10. Anttila A, von Karsa L, Aasmaa A et al. Cervical cancer screening policies and coverage in Europe. Eur. J. Cancer DOI:1 0.1016/j.ejca.2009.07.020 (2009) (Epub ahead of print).
11. Arbyn M, Rebolj M, De Kok IM et al. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur. J. Cancer DOI: 10.1016/j.ejca.2009.07.016 (2009) (Epub ahead of print).
12. Nicula FA, Anttila A, Neamtiu L et al. Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. Eur. J. Cancer DOI: 10.1016/j.ejca.2009.07.025 (2009) (Epub ahead of print).
13. European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening (Second Edition). Arbyn M, Anttila A, Jordan J et al. (Eds). Office for Official Publications of the European Communities, Luxembourg, Luxembourg (2008). •• First complete and detailed European guideline for successful implementation of an organized cervical cancer screening program.
14. Lévy-Bruhl D, Bousquet V, King LA et al. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 Survey. Eur. J. Cancer DOI: 10.1016/j.ejca.2009.07. 023 (2009) (Epub ahead of print).
15. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am. J. Epidemiol. 141(7), 680-689 (1995).
16. Karnon J, Peters J, Platt J et al. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol. Assess. 8(20), iii, 1-78 (2004) (Pubitemid 38812219)
17. Kitchener HC, Almonte M, Thomson C et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 10(7), 672-682 (2009). • Randomised trial comparing liquid-based cytology (LBC) and human papillomavirus (HPV) testing against LBC alone in primary screening.
18. Arbyn M, Bergeron C, Klinkhamer P et al. Liquid compared with conventional cervical cytology. Obstet. Gynecol. 111(1), 167-177 (2008). • Study comparing LBC with conventional cytology.
19. Arbyn M, Buntinx F, Van Ranst M et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl Cancer Inst. 96(4), 280-293 (2004). •• Meta-analysis indicating that HPV testing has improved accuracy (higher sensitivity, similar specificity) than the repeat Pap smear. (Pubitemid 38256273)
20. Cuzick J, Sasieni P, Davies P et al. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br. J. Cancer 83(5), 561-565 (2000). (Pubitemid 30636292)
21. Arbyn M, Martin-Hirsch P, Buntinx F et al. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J. Cell Mol. Med. 13(4), 648-659 (2009).
22. Cuzick J, Szarewski A, Cubie H et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362(9399), 1871-1876 (2003).
23. Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119(5), 1095-1101 (2006). • Reviews similar large-scale studies of the accuracy of HPV testing and cytology. (Pubitemid 44116919)
24. Grce M, Davies P. Human papillomavirus testing for primary cervical cancer screening. Expert Rev. Mol. Diagn. 8(5), 599-605 (2008).
25. Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year followup of a randomised controlled implementation trial. Lancet 370(9601), 1764-1772 (2007). (Pubitemid 350137476)
26. Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26(Suppl. 10), K29-K41 (2008).
27. Qiao YL, Sellors JW, Eder PS et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a crosssectional study of clinical accuracy in rural China. Lancet Oncol. 9(10), 929-936 (2008). • New HPV DNA screening test for low-income countries.
28. Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360(14), 1385-1394 (2009). • Randomized clinical trial comparing different screening strategies in low-income countries.
29. Carozzi F, Confortini M, Dalla Palma P et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 9(10), 937-945 (2008). • Evaluation of HPV testing with p16-INK4A triage and conventional cytology in cervical screening.
30. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356(19), 1915-1927 (2007). •• Findings of the clinical trial evaluating the quadrivalent HPV vaccine.
31. Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686), 301-314 (2009). •• Findings of the clinical trial evaluating the bivalent HPV vaccine.
32. Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199(7), 926-935 (2009).
33. Wheeler CM, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 199(7), 936-944 (2009).
34. Clifford GM, Smith JS, Plummer M et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88(1), 63-73 (2003). (Pubitemid 36241220)
35. Franco EL, Cuzick J, Hildesheim A, de Sanjosé S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24(Suppl. 3), 171-177 (2006). (Pubitemid 44293022)
36. Gao S. Development of HPV and HEV vaccines. Presented at: 8th Developing Countries Vaccine Manufacturers' Network (DCVMN) Annual General Meeting. Rio de Janiero, Brazil, 12 November 2007. • New bivalent vaccine for low-income countries.
37. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. Ferlay J, Bray F, Pisani P, Parkin DM (Eds). IARC Press, Lyon, France (2004) www-dep.iarc.fr/
38. GDP, Gross Domestic Product. The World Bank. Data and Statistics (2008) http://siteresources.worldbank.org/ DATASTATISTICS/Resources/GDP.pdf
39. European Cervical Cancer Association. HPV vaccination across Europe. ECCA. (2009) www.ecca.info/fileadmin/user-upload/ HPV-Vaccination/ECCA-HPV- Vaccination-April-2009.pdf.
40. WHO. Human papillomavirus (HPV) vaccine background paper (2008) www.who.int/immunization/documents/ HPVBGpaper-final-03-04-2009.pdf •• Summary of findings of clinical trials of both current HPV vaccines commercially available.